Price T Rowe Associates Inc Aquestive Therapeutics, Inc. Transaction History
Price T Rowe Associates Inc
- $867 Billion
- Q4 2024
A detailed history of Price T Rowe Associates Inc transactions in Aquestive Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 27,669 shares of AQST stock, worth $83,283. This represents 0.0% of its overall portfolio holdings.
Number of Shares
27,669
Previous 23,848
16.02%
Holding current value
$83,283
Previous $119,000
16.81%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding AQST
# of Institutions
121Shares Held
43.3MCall Options Held
504KPut Options Held
148K-
Bratton Capital Management, L.P. Fort Worth, TX9.81MShares$29.5 Million100.0% of portfolio
-
Black Rock Inc. New York, NY5.45MShares$16.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.35MShares$13.1 Million0.0% of portfolio
-
Vr Adviser, LLC New York, NY2.63MShares$7.92 Million1.54% of portfolio
-
Franklin Resources Inc San Mateo, CA2.13MShares$6.43 Million0.0% of portfolio
About Aquestive Therapeutics, Inc.
- Ticker AQST
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,350,700
- Market Cap $161M
- Description
- Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual f...